Buy Dr Reddys Laboratories, says Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that, one should buy Dr Reddys Laboratories.

Sukhani told CNBC-TV18, "Two days of narrow ranges, two days of confusion after the big rally and the Nifty itself is in a narrow range for the last two days. The SGX suggests, it is going to breakout on the upside, but that is almost exactly what I expect some of the good stocks to do. Therefore, Dr Reddys is a buying opportunity. Do not worry about lifetime highs, they should be bought into." The company's trailing 12-month (TTM) EPS was at Rs 51.10 per share. (Dec, 2012). The stock's price-to-earnings (P/E) ratio was 39.53. The latest book value of the company is Rs 395.55 per share. At current value, the price-to-book value of the company was 5.11. The dividend yield of the company was 0.68 percent. Disclosure: Sudarshan Sukhani has no holdings in the stocks discussed.